These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 37460004)
1. Recent advances in the management and implementation of care for familial hypercholesterolaemia. Lan NSR; Bajaj A; Watts GF; Cuchel M Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004 [TBL] [Abstract][Full Text] [Related]
2. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Page MM; Stefanutti C; Sniderman A; Watts GF Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720 [TBL] [Abstract][Full Text] [Related]
5. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
6. Homozygous familial hypercholesterolemia: what treatments are on the horizon? Bajaj A; Cuchel M Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430 [TBL] [Abstract][Full Text] [Related]
7. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941 [TBL] [Abstract][Full Text] [Related]
9. Homozygous familial hypercholesterolaemia: update on management. France M Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828 [TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159 [TBL] [Abstract][Full Text] [Related]
12. Existing and emerging therapies for the treatment of familial hypercholesterolemia. Rosenson RS J Lipid Res; 2021; 62():100060. PubMed ID: 33716107 [TBL] [Abstract][Full Text] [Related]
13. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071 [TBL] [Abstract][Full Text] [Related]
14. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies. Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803 [TBL] [Abstract][Full Text] [Related]
15. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia. Bajaj A; Cuchel M J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL; J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591 [TBL] [Abstract][Full Text] [Related]
17. Familial Hypercholesterolemia: Global Burden and Approaches. Tokgozoglu L; Kayikcioglu M Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646 [TBL] [Abstract][Full Text] [Related]
18. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibition in the management of familial hypercholesterolemia. Ogura M J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Pirillo A; Catapano AL; Norata GD Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]